Bristol Myers Squibb presents results from CheckMate – 8HW analysis evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) compared to Opdivo monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025